AZN logo

AstraZeneca PLC

AZN
Healthcare|Drug Manufacturers - General|GB
$186.43
-0.42 (-0.22%)
DCF Value
$500.17
Graham Number
$72.85
Cash / Share
$5.23

Analyst Consensus

Buy41 analysts
Strong Buy
1
Buy
19
Hold
15
Sell
6
Strong Sell
0
Consensus Target
$186.67
Implied Upside
+0.1%
Low Target
$158.00
High Target
$216.00

Price Target Trend

Last Month
—
0 targets
Last Quarter
—
0 targets
Last Year
$211.00
2 targets · +13% vs price
All Time
$175.64
11 targets · -6% vs price

Rating Trend

Dec 25
10 buy · 1 hold · 0 sell
Jan 26
10 buy · 1 hold · 0 sell
Feb 26
10 buy · 1 hold · 1 sell
Mar 26
8 buy · 1 hold · 1 sell
Apr 26
9 buy · 1 hold · 0 sell
May 26
9 buy · 1 hold · 0 sell
Jun 26
9 buy · 1 hold · 0 sell
Jul 26
9 buy · 2 hold · 0 sell
Aug 26
10 buy · 2 hold · 0 sell
Sep 26
10 buy · 1 hold · 0 sell
Oct 26
10 buy · 2 hold · 1 sell
Nov 26
9 buy · 2 hold · 1 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Dec 10, 2025HSBC$108.00(-40%)$179.64TheFly
Dec 3, 2025Morgan Stanley$103.00(-43%)$180.34TheFly
Jul 9, 2025Berenberg BankLuisa Hector$97.00(-32%)$141.64TheFly
Nov 13, 2024BMO CapitalEtzer Darout$88.00(-46%)$162.38StreetInsider
Sep 11, 2024BMO CapitalEtzer Darout$89.00(-44%)$159.88StreetInsider
May 30, 2024Argus ResearchJohn Eade$85.00(-45%)$153.68StreetInsider
May 28, 2024BMO CapitalEtzer Darout$82.00(-47%)$153.48StreetInsider
Jul 12, 2023Leerink PartnersAndrew Berens$79.00(-39%)$129.72Benzinga
Jan 5, 2023BMO Capital$82.00(-41%)$139.00Benzinga
Nov 11, 2022Leerink Partners$78.00(-40%)$130.18Benzinga
May 4, 2022Leerink Partners$75.00(-44%)$134.34Benzinga

Recent Rating Actions

FirmActionRatingDate
UBSupgradeNeutral →BuyFeb 13, 2025
UBSupgradeSell →NeutralNov 20, 2024
Erste GroupupgradeHold →BuySep 11, 2024
TD CowenmaintainBuyAug 12, 2024
Argus ResearchmaintainBuyMay 30, 2024
BMO CapitalmaintainOutperformApr 26, 2024
Deutsche BankupgradeSell →HoldApr 16, 2024
BMO CapitalmaintainOutperformFeb 12, 2024
Deutsche BankdowngradeBuy →HoldFeb 8, 2024
JefferiesdowngradeBuy →HoldJan 3, 2024
JefferiesupgradeHold →BuySep 25, 2023
Erste GroupdowngradeBuy →HoldSep 8, 2023
BMO CapitalmaintainOutperformAug 1, 2023
Argus ResearchmaintainBuyMay 26, 2023
Argus ResearchmaintainBuyApr 13, 2023
SVB LeerinkmaintainOutperformNov 14, 2022
SVB LeerinkmaintainOutperformNov 11, 2022
Argus ResearchupgradeHold →BuyAug 29, 2022
SVB LeerinkmaintainOutperformMay 4, 2022
SVB LeerinkmaintainOutperformFeb 24, 2022
DZ BankupgradeSell →HoldFeb 11, 2022
JefferiesdowngradeBuy →HoldDec 7, 2021
SVB LeerinkmaintainOutperformSep 27, 2021
SVB LeerinkmaintainOutperformSep 20, 2021
SVB LeerinkmaintainOutperformAug 4, 2021

Earnings History

Next report: Feb 9, 2027 · EPS est. $2.32
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Oct 30, 2026$2.79$2.60$16.21B$16.00B
Jul 27, 2026$2.63$2.50$15.38B$15.44B
Apr 29, 2026$2.58$2.57$15.29B$14.93B
Feb 10, 2026$2.12$2.09$15.50B$15.44B
Nov 6, 2025$2.38$2.28$15.19B$14.78B
Jul 29, 2025$2.18$2.18$14.46B$14.10B
Apr 29, 2025$2.48$2.20$13.59B$13.81B
Feb 6, 2025$2.10$2.07$14.89B$14.23B

News

AstraZeneca Plc (NYSE:AZN) Stock Has Average Price Target of $206.67 According to Brokerages

AstraZeneca Plc (NYSE: AZN - Get Free Report) has received a consensus rating of "Moderate Buy" from the nineteen ratings firms that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average 1 year price target

Nov 6, 2026defenseworld.net
AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals

AstraZeneca recently made a roughly $10 billion offer to buy Rhythm Pharmaceuticals, according to people familiar with the matter, a deal that would expand its portfolio of rare disease treatments.

Nov 4, 2026wsj.com
27,056 AstraZeneca Plc $AZN Shares Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC boosted its stake in AstraZeneca Plc (NYSE: AZN) by 1,564.8% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 28,785 shares of the company's stock after purchasing an additional 27,056 shares during the period. International Assets Investment Management LLC's holdings in

Nov 2, 2026defenseworld.net
1,929,102 Shares of AstraZeneca Plc $AZN Acquired by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer and Co. Ltd Zurich bought a new stake in AstraZeneca Plc (NYSE: AZN) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,929,102 shares of the company's stock, valued at approximately $314,403,000. Bank Julius Baer and Co. Ltd

Nov 2, 2026defenseworld.net
AstraZeneca: 3 Key Takeaways for Long-Term Investors

Total revenue grew 7% across the first nine months of 2026. AstraZeneca launched a $2 billion restructuring initiative through 2029.

Nov 1, 2026fool.com
AstraZeneca (NYSE:AZN) Share Price Crosses Above 200 Day Moving Average – Time to Sell?

AstraZeneca Plc (NYSE: AZN - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $180.21 and traded as high as $188.39. AstraZeneca shares last traded at $186.49, with a volume of 5,464,384 shares traded. Key Headlines Impacting AstraZeneca Here are the key

Oct 31, 2026defenseworld.net
AstraZeneca Plc $AZN Shares Acquired by Brian Low Financial Group LLC

Brian Low Financial Group LLC increased its position in shares of AstraZeneca Plc (NYSE: AZN) by 32.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,203 shares of the company's stock after buying an additional 3,491 shares during

Oct 31, 2026defenseworld.net
AstraZeneca (LON:AZN) Share Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

AstraZeneca PLC (LON: AZN - Get Free Report) passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of £134.30 and traded as high as £140.02. AstraZeneca shares last traded at £139.96, with a volume of 40,274,711 shares changing hands. Trending Headlines about AstraZeneca Here are the key news

Oct 31, 2026defenseworld.net
AstraZeneca PLC (AZN) Q3 2026 Earnings Call Transcript

AstraZeneca PLC (AZN) Q3 2026 Earnings Call Transcript

Oct 31, 2026seekingalpha.com
AstraZeneca Q3 Earnings Call Highlights

AstraZeneca NYSE: AZN reported continued revenue and earnings growth for the first nine months of 2026, supported by double-digit expansion in oncology, rare disease and respiratory and immunology, while loss-of-exclusivity pressures weighed on parts of its cardiovascular, renal and metabolism portfolio.

Oct 30, 2026marketbeat.com
AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth

AstraZeneca beats Q3 earnings and revenue estimates as oncology sales surge 17%, offsetting generic pressure on mature drugs.

Oct 30, 2026zacks.com
AstraZeneca Stock Rallies on Q3 Earnings Beat, Double-Digit Oncology Growth

AstraZeneca Plc (NYSE:AZN) on Friday posted better-than-expected third-quarter 2026 results. The European drug giant reported core earnings of $2.79 per share, beating the consensus of $2.59.

Oct 30, 2026benzinga.com
Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Oct 30, 2026zacks.com
AstraZeneca CFO on AI, Earnings, Restructuring Plan

AstraZeneca Chief Financial Officer Aradhana Sarin says the drug company uses AI in almost every aspect of the work they do. She talks beating on earnings, their drug pipeline and how the company approaches dealmaking.

Oct 30, 2026youtube.com
AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock

AstraZeneca aims to free up funds to reinvest into its pipeline and meet its goal of $80 billion in annual revenue by 2030.

Oct 30, 2026barrons.com
AstraZeneca results: 9M and Q3 2026

CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary   9M 2026 % Change Q3 2026 % Change   $m Actual CER1 $m Actual CER - Product Sales 43,962 7 5 15,066 5 5 - Alliance Revenue 2,806 33 32 1,107 36 36 Product Revenue 46,768 8 6 16,173 7 7 Collaboration Revenue 113 22 23 36 >3x >3x Total Revenue 46,881 8 7 16,209 7 7 Reported EPS ($) 5.62 10 11 2.02 23 26 Core2 EPS ($) 8.00 14 14 2.79 17 19 Key performance elements for 9M 2026 (Growth numbers at constant exchange rates.

Oct 30, 2026businesswire.com
FTSE 100 set for monthly gains; AstraZeneca up after results

London's FTSE 100 ​looked on track to log its first monthly gain in three ‌months, edging up on Friday as AstraZeneca rose, with investors welcoming a budget that was softer than expected on taxes.

Oct 30, 2026reuters.com
AstraZeneca Posts Revenue, Profit Growth on Strong Cancer-Drug Sales

The U.K. drugmaker reported net profit of $3.12 billion for the third quarter, up from $2.535 billion for the same period last year.

Oct 30, 2026wsj.com
AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the launch of Meet Your Mark, a new public health campaign featuring actor Mark-Paul Gosselaar. The campaign encourages people to ask about biomarker testing if they or a loved one is diagnosed with cancer, helping make biomarker testing a standard part of the cancer care conversation. Leaning into nostalgia for audiences who watched him early in his career, Mark-Paul acts as a warm, relatable guide showing how biomarker testing may.

Oct 28, 2026businesswire.com
Allspring Emerging Growth Fund: Q3 2026 Top Contributors And Detractors

After delivering results well above expectations, TWST management significantly raised its outlook and projected triple-digit growth in orders. During the quarter, LIFE shares performed well following a strong earnings beat. During the quarter, several key approvals and coverage expansions supported product growth for GH.

Oct 28, 2026seekingalpha.com